NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals

Molecular Medicine

Gordana Bogdanovic¹  Sandra Muschiol²  Gunnar Söderdahl³  Giorgio Gabarrini⁴  Michal J. Sobkowiak⁴  Margaret Sällberg Chen⁴  Katie Healy⁴  Per Ljungman⁵  Ola Blennow⁶  Peter Bergman⁷  C. I. Edvard Smith⁸  Soo Aleman⁹  Piotr Nowak^1,10  Stephan Mielke^1,11  Joshua Lange^1,12  Johan K. Sandberg^1,12  Marcus Buggert^1,12  Mira Akber^1,12  Tobias Kammann^1,12  Benedikt Strunz^1,12  Yu Gao^1,12  David Wullimann^1,12  Niklas K. Björkström^1,12  Quirin Hammer^1,12  Jagadeeswara Rao Muvva^1,12  Tiphaine Parrot^1,12  André Pérez Potti^1,12  Olga Rivera Ballesteros^1,12  Angelica Cuapio^1,12  Hans-Gustaf Ljunggren^1,12  Caroline Boulouis^1,12  Iva Filipovic^1,12  Puran Chen^1,12  Evren Alici^1,13  Fredrika Hellgren^1,14  Karin Loré^1,14  Anders Österborg^1,15  Lotta Hansson^1,15 

[1] Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden;Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden;Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden;Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden;Department of Transplantation, Karolinska University Hospital, Stockholm, Sweden;Department of Dental Medicine, Karolinska Institutet, Stockholm, Sweden;Department of Hematology, Karolinska University Hospital, Stockholm, Sweden;Department of Cellular Therapy and Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital Huddinge, Stockholm, Sweden;Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden;Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden;Department of Transplantation, Karolinska University Hospital, Stockholm, Sweden;Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden;Department of Laboratory Medicine, Clinical Microbiology, Karolinska Institutet, Stockholm, Sweden;Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden;Department of Laboratory Medicine, Translational Research Center Karolinska (TRACK), Karolinska Institutet, Stockholm, Sweden;Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden;Department of Medicine Huddinge, Infectious Diseases, Karolinska Institutet, Stockholm, Sweden;Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden;Department of Medicine Huddinge, Infectious Diseases, Karolinska Institutet, Stockholm, Sweden;Laboratory for Molecular Infection Medicine Sweden MIMS, Umeå University, Umeå, Sweden;Department of Laboratory Medicine, Biomolecular and Cellular Medicine, Karolinska Institutet, Stockholm, Sweden;Department of Cellular Therapy and Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital Huddinge, Stockholm, Sweden;Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden;Department of Medicine Huddinge, Hematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden;Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden;Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden;Department of Hematology, Karolinska University Hospital, Stockholm, Sweden;

关键词: Anti-SARS-CoV-2 antibodies;    BNT162b2 mRNA vaccine;    Clinical trial;    COVID-19;    NK cells;    Innate immunity;    mRNA vaccine;    NKG2C;    SARS-CoV-2;   

DOI  :  10.1186/s10020-022-00443-2

来源: Springer

【 摘 要 】

Adaptive immune responses have been studied extensively in the course of mRNA vaccination against COVID-19. Considerably fewer studies have assessed the effects on innate immune cells. Here, we characterized NK cells in healthy individuals and immunocompromised patients in the course of an anti-SARS-CoV-2 BNT162b2 mRNA prospective, open-label clinical vaccine trial. See trial registration description in notes. Results revealed preserved NK cell numbers, frequencies, subsets, phenotypes, and function as assessed through consecutive peripheral blood samplings at 0, 10, 21, and 35 days following vaccination. A positive correlation was observed between the frequency of NKG2C+ NK cells at baseline (Day 0) and anti-SARS-CoV-2 Ab titers following BNT162b2 mRNA vaccination at Day 35. The present results provide basic insights in regards to NK cells in the context of mRNA vaccination, and have relevance for future mRNA-based vaccinations against COVID-19, other viral infections, and cancer.Trial registration: The current study is based on clinical material from the COVAXID open-label, non-randomized prospective clinical trial registered at EudraCT and clinicaltrials.gov (no. 2021–000175-37). Description: https://clinicaltrials.gov/ct2/show/NCT04780659?term=2021-000175-37&draw=2&rank=1.

【 授权许可】

CC BY